Business Wire

Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment

Share

Celltrion Group today announced top-line efficacy and safety data from the global Phase III clinical trial, demonstrating that anti-COVID-19 monoclonal antibody treatment candidate, regdanvimab (CT-P59), met all primary and key secondary endpoints in patients with mild- to- moderate symptoms of COVID-19 (n=1,315). Results showed that CT-P59 significantly reduced the risk of hospitalisation or death by 72% for patients at high- risk of progressing to severe COVID-19 up to Day 28, compared to placebo, meeting the primary efficacy endpoint [3.1 vs. 11.1 %, p-value< 0.0001]. CT-P59 also significantly reduced the risk of hospitalisation or death by 70% in all patients, meeting the first key secondary endpoint [2.4 vs. 8.0 %, p-value< 0.0001].

The trial also met the other key secondary endpoints, including faster and persistent reduction in symptom duration. Patients treated with CT-P59 (40mg/kg) recovered at least 4.7 days earlier than those in the placebo-treated patients [median 9.3 vs. minimum 14 days, p-value< 0.0001] for patients at high- risk of progressing to severe COVID-19. For all patients treated with CT-P59 (40mg/kg), patients recovered 4.9 days earlier than those in the placebo-treated patients [median 8.4 vs. 13.3 days, p-value< 0.0001].

Top-line results also showed CT-P59 to have a positive safety profile, with no clinically meaningful differences between patients treated with CT-P59 (40mg/kg) and placebo-treated patients. Infusion related reactions were mild and transient, with most patients recovering within 1~3 days.

“We continue to be challenged by the COVID-19 pandemic and new variants of concern,” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. “As many hospitals across the globe now exceed their ability to accommodate patients due to COVID-19, it is critical that we use every resource to reduce the burden on the healthcare system. This well-controlled trial provides conclusive results demonstrating that CT-P59 can improve outcomes in people with mild- to- moderate COVID-19 and also significantly reduce the risk of hospitalisation and death. We look forward to continuing to work with regulators around the world to make CT-P59 available to more patients in need.”

Therapeutic effect of CT-P59 against B.1.351 variant (first identified in South Africa, now classified by the WHO as Beta) was updated through the publication from Biochemical and Biophysical Research Communications. According to the article, in vivo ferret challenge studies demonstrated that a therapeutic dosage of CT-P59 was able to decrease B.1.351 viral load in the upper and lower respiratory tracts, comparable to that observed for the wild type virus.1

Celltrion plans to release full Phase III data in the coming months and plans to present the data at an oral session at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will take place online from 9 -12 July 2021.

- ENDS -

Notes to Editors:

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us.

About regdanvimab (CT-P59) and clinical trials

CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus. In vitro and in vivo pre-clinical studies showed that CT-P59 strongly binds to SARS-CoV-2 RBD and significantly neutralise the wild type and mutant variants of concern including the Alpha UK variant (B.1.17). In in vivo models, CT-P59 effectively reduced the viral load of SARS-CoV-2 and inflammation in lung. Results from the global Phase I and II clinical trials of CT-P59 demonstrated a promising safety, tolerability, antiviral effect and efficacy profile in patients with mild- to- moderate symptoms of COVID-19.2 Celltrion also has recently commenced the development of a neutralising antibody cocktail with CT-P59 against new emerging variants of SARS-CoV-2. The research for Celltrion’s clinical trials was supported by a grant as part of the Korea Health Technology R&D Project from the Korea Health Industry Development Institute (KHIDI), funded by the ministry of Health & Welfare, Republic of Korea (grant number: HQ2xC00xx).

FORWARD LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References


1 Ryu DK., et al. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochemical and Biophysical Research Communications, Volume 566, 2021, Pages 135-140, https://doi.org/10.1016/j.bbrc.2021.06.016. [Last accessed June 2021]

2 Celltrion Data on file

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Barber
hbarber@hanovercomms.com
+44 (0) 7759 301620

Donna Curran
dcurran@hanovercomms.com
+44 (0) 7984 550312

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Reports Second Quarter 2021 Results5.8.2021 23:15:00 EEST | Press release

International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the second quarter ended June 30, 2021. Management Commentary "We delivered a strong second quarter performance, with double-digit sales growth and a solid improvement in overall profitability," said IFF Chairman and CEO Andreas Fibig. “Both businesses performed well – with legacy IFF growing strong double-digits and legacy N&B improving mid-single digits – all while we continue to successfully integrate two great organizations. Our synergy realization is on track and the overall business performance underscores the strength and diversity of our portfolio as well as our position as an essential partner to our customers." IFF Executive Vice President and CFO, Rustom Jilla commented, “Profit and free cash flow were both solid in the second quarter, with broad-based improvements versus the year-ago period. We continued to optimize our cost structure, implement price increases and capture cost synergies to s

Rollic Surpasses 1 Billion Total Downloads Worldwide5.8.2021 23:08:00 EEST | Press release

Rollic, a subsidiary of Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced today a studio milestone of surpassing 1 billion downloads across its diverse portfolio of hyper-casual games. As one of the largest hyper-casual publishers in the world, Rollic has created a unique development process that leverages data insights and rigorous testing to repeatedly design and publish hit hyper-casual titles. Rollic’s process generates universally fun game concepts that resonate in pop culture and quickly spread on leading social media networks like TikTok. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005074/en/ Rollic Surpasses 1 Billion Total Downloads Worldwide Rollic’s fast-growing portfolio includes 15 titles that have reached the #1 or #2 top free downloaded games position in the U.S. App Store. Breakout hits Hair Challenge, High Heels! and Tangle Master 3D have each generated over 100 mill

Zynga Enters Into Agreement to Acquire Mobile Game Developer StarLark, Team Behind the Hit Franchise, Golf Rival5.8.2021 23:07:00 EEST | Press release

Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, today announced it has entered into a definitive agreement to acquire StarLark, developer of the fast-growing and second-largest mobile golf game in the world, Golf Rival, from Betta Games for $525 million in cash and stock. This acquisition brings to Zynga a talented development team with the proven ability to create a global hit and additional projects in early development. StarLark also expands Zynga’s international presence by establishing a China-based studio with access to the region’s creative talent base. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005098/en/ Zynga Enters Into Agreement to Acquire Mobile Game Developer StarLark, Team Behind the Hit Franchise, Golf Rival (Graphic: Business Wire) In Golf Rival, players of all skill levels compete in real-time player-versus-player matches, including multiplayer tournaments on spectacular c

Zynga Announces Second Quarter 2021 Financial Results5.8.2021 23:05:00 EEST | Press release

Zynga Inc. (Nasdaq: ZNGA) today released financial results for its first quarter ending June 30, 2021 by posting management’s Q2 2021 Quarterly Earnings Letter to its Investor Relations website. Please refer to the attached Quarterly Earnings Letter or visit http://investor.zynga.com/financial-information/quarterly-results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005959/en/ ZYNGA ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS (Graphic: Business Wire) “We completed a strong first half of 2021, delivering Q2 results ahead of our guidance, including our best-ever Q2 revenue, bookings and operating cash flow. Our multi-year strategy of growing our live services, launching new games and investing in global expansion continues to position Zynga for growth,” said Frank Gibeau, Chief Executive Officer of Zynga. “Today, we are thrilled to officially welcome the Chartboost team to Zynga, as well as announce an agreement

UAVita Systems Together With Nova Poshta Successfully Completed the World’s First Civilian Long Range Intercity Autonomous Drone Flight5.8.2021 22:58:00 EEST | Press release

On July 29, 2021, UAVita Systems made history with a world aviation industry first – autonomous drone delivery of commercial packages between two major cities. The Nova poshta commercial flight of UAVita’s DISCOVERY D-80 drone between Kyiv and Kharkiv, two major cities in Ukraine, was 480 km between takeoff and landing and carried a load of five parcels for delivery. The flight was fully autonomous from takeoff to waypoint navigation to landing and crossed several rivers, highways, avoiding populated areas, infrastructure objects and restricted airspace. Airspace for the flight was reserved with local air traffic control, state air services, and several military authorities. The flight was operated by UAVita’s local Ukraine company, Aerodrone. "The flight went exactly as planned," said Yuri Pederiy, CTO of UAVita. "Nova poshta was very pleased with the results." DISCOVERY’s average air speed was 100 kph, with an altitude of 300 meters and total flight time was 4:45 hours a full hour ah

P&G Puts Athletes Who Lead with Love Center Stage at Olympic Games Tokyo 2020, Celebrating Their Efforts and Inspiring Positive Action in Others5.8.2021 21:49:00 EEST | Press release

As an Olympic sponsor for the past 10 years, Procter & Gamble’s (NYSE: PG) focus is on celebrating and supporting the unique journeys athletes take on the road to their Olympic dreams, including the causes they champion and the work they do to drive positive change in their communities. In the lead up to the Olympic Games Tokyo 2020, P&G was inspired by the selfless actions of Olympic and Paralympic athletes around the world who stepped up and served others. This led P&G to create the Athletes for Good Fund in partnership with the International Olympic Committee (IOC) and International Paralympic Committee (IPC). Its purpose is to honor and fuel the work of Olympic and Paralympic athletes and hopefuls who lend their time, talent, and resources to charitable causes in the areas of Community Impact, Equality & Inclusion, and Environmental Sustainability. For Tokyo 2020, Athletes for Good Fund provided more than $500,000 in grants to help fuel the efforts of the recipients’ charities of c

Champion® Athleticwear Unveils Second Capsule in Muhammad Ali Collection5.8.2021 20:02:00 EEST | Press release

Champion, makers of authentic athletic apparel since 1919, and Muhammad Ali Enterprises, today dropped the second, limited-edition capsule in Champion’s Muhammad Ali Collection. The capsule’s new designs and fresh colors are fabricated to evoke the ethos of the sports legend during his inspirational gold medal win during the 1960 Games in Rome as an 18-year-old. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005624/en/ With details based on the 1960 Games historic location and team uniforms, Champion's Muhammad Ali collection features unique athletic accents, iconic silhouettes, luxe fabrics and voluminous draping. The men’s and women’s apparel includes Reverse Weave® hoodies, quarter-zip pullovers, joggers, shorts, graphic T-shirts, crop tops, bike shorts, hats and a special satin boxing robe. The collection is being distributed via Champion.com and Champion retail stores with distribution in the United States, Europe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom